Sweating dysfunctions in Parkinson's disease.
There is a high frequency of dyshidrosis in Parkinson's disease. Daily use of an antiparkinsonian drug does not affect sweating. Mental sweating relates to the contraction period and seriousness. However, hyperthermic sweating does not necessarily relate to the contraction period or seriousness. Abnormalities in mental sweating are not necessarily correlated with cardiovascular autonomic disturbances. As the autonomic disturbance becomes more advanced, dyshidrosis becomes more common. Hyperhidrosis may develop with dyskinesia. Hyperhidrosis may be improved by the temporally administration of levodopa. Dyshidrosis might be caused by a centrally-acting abnormality during its early stage. However, postganglional abnormalities as well as central changes may increase as the disease progresses. The presence of dyshidrosis affects the QOL and depression in patients with Parkinson's disease. The only therapy for hyperhydrotic sweating disorders is the administration of levodopa or dopaminagonist. Additional studies including therapy for sweating disorders are necessary.
Hirayama
Masaaki
M
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. hirasan@med.nagoya-u.ac.jp
D006801:Humans; D006945:Hyperhidrosis / Q000150:complications* / Q000209:etiology*; D010300:Parkinson Disease / Q000150:complications*; D013546:Sweating / Q000502:physiology*